Skip to main content

Table 4 Changes of echocardiographic parameters after 3 months of placebo treatment

From: Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

  Mean ± standard deviation 95% CI (mean) median and interquartile ranges
Parameter N lower limit upper limit
Echocardiography
 right atrial area [cm2] 5 −0.4 ± 2.9 −4.1 3.2 1 [−3.2; 2]
 right ventricular area [cm2] 5 2.0 ± 6.4 −6.0 9.8 0 [−5.3; 10]
 TAPSE [mm] 5 0.5 ± 3.3 −3.6 4.5 0 [−2.6; 6]
 RV thickness [mm] 4 1.0 ± 0.8 −0.3 2.3 1.0 [0.5; 1.5]
 TRV [cm/sec] 4 0.1 ± 0.2 −0.3 0.4 0.1 [−0.1; 0.3]
 IVC diameter [mm] 5 −0.4 ± 2.7 −3.8 2.9 0 [0; 0.8]
 LV-EI 5 −0.1 ± 0.1 −0.2 0.03 −0.1 [− 0.2; 0]
 PA diameter [mm] 4 −0.25 ± 1.3 −2.3 1.8 0 [−1.0; 0.5]
  1. TAPSE = tricuspid annular plane systolic excursion; FAC = Fractional area change; RV = right ventricular
  2. TRV tricuspid regurgitation velocity, IVC inferior vena cava, LV-EI left ventricular eccentricity index
  3. PA pulmonary artery